Xenazine approved for Huntington's disease
Xenazine (tetrabenazine tablets, from Prestwick) has been FDA approved for the treatment of chorea associated with Huntington's disease (HD). This approval was based on results from a double-blind, placebo-controlled study which found that Xenazine significantly reduced patients' chorea burden and improved global outcome scores.
Xenazine, a monoamine depletor, is expected to be available in 2008 in 12.5mg and 25mg dosage strengths.
For more information call (202) 296-1400 or visit www.prestwickpharma.com.